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Abstract
Purpose: Little is known about prevalence and treatment of OUD among youth engaged in primary care (PC). Medications are the recommended treatment of opioid use disorder (OUD) for adolescents and young adults (youth). This
study describes the prevalence of OUD, the prevalence of medication treatment for OUD, and patient characteristics
associated with OUD treatment among youth engaged in PC.
Methods: This cross-sectional study includes youth aged 16–25 years engaged in PC. Eligible patients had ≥ 1 PC
visit during fiscal years (FY) 2014–2016 in one of 6 health systems across 6 states. Data from electronic health records
and insurance claims were used to identify OUD diagnoses, office-based OUD medication treatment, and patient
demographic and clinical characteristics in the FY of the first PC visit during the study period. Descriptive analyses
were conducted in all youth, and stratified by age (16–17, 18–21, 22–25 years).
Results: Among 303,262 eligible youth, 2131 (0.7%) had a documented OUD diagnosis. The prevalence of OUD
increased by ascending age groups. About half of youth with OUD had documented depression or anxiety and one
third had co-occurring substance use disorders. Receipt of medication for OUD was lowest among youth 16–17 years
old (14%) and highest among those aged 22–25 (39%).
Conclusions: In this study of youth engaged in 6 health systems across 6 states, there was low receipt of medication
treatment, and high prevalence of other substance use disorders and mental health disorders. These findings indicate
an urgent need to increase medication treatment for OUD and to integrate treatment for other substance use and
mental health disorders.
Keywords: Opioid use disorder, Adolescents, Young adults, Medication for opioid use disorder, Buprenorphine,
Naltrexone
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Introduction
Opioid-related deaths continue to increase in the United
States among adolescents and young adults (youth) [1].
Between 1999 and 2016, the opioid-related mortality rate
increased 252% among 15–19 year olds [2]. Similar to the
adult population, the rise in deaths is driven by illicitlymanufactured fentanyl, which is about 100 times more
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potent than morphine and 50 times more potent than
heroin [2, 3]. Emergency department visits and intensive
care unit admissions related to opioid poisonings among
youth have also increased [2].
Rising opioid-related deaths have led to efforts to
increase access to medication for opioid use disorder
(OUD) for all ages [4, 5]. Medication is considered the
gold standard for treatment of OUD and improves OUD
patient outcomes, including abstinence, retention in care,
and survival [6–9]. Although federal regulations limit
access to methadone as a treatment for OUD for youth
younger than 18 years, two of the FDA-approved medications for OUD (i.e., buprenorphine and naltrexone) can
be prescribed in primary carethat care for youth (PC;
e.g., office-based settings).
The American Academy of Pediatrics and the American Society for Addiction Medicine recommend that
youth with OUD be treated medication [6, 10, 11].
Despite these recommendations, youth with OUD are
often not treated with medication. In studies of both publicly and commercially insured youth with a diagnosis of
OUD, only 4.5% of adolescents younger than 18 years and
one in four young adults 18–22 years old received medications for OUD within three months of diagnosis [12,
13]. Recent national U.S. data indicate that populationbased rates of buprenorphine prescriptions decreased
among 15–34 year olds from 2009 to 2018, in contrast to
all other age groups [14]. None of these studies examined
whether patients were engaged in PC. Engagement in PC
may represent an important opportunity to offer medications for OUD to youth; most youth in the US see a PC
provider and some have long-standing trusting relationships with them.
In the present study, we evaluated the prevalence of
OUD and office-based medication treatment for OUD
in a large sample of youth and young adults aged 16–25
(hereafter “youth”) who received PC in one of 6 health
systems across 6 states. The objectives of this study
were to describe, among youth engaged in PC, (1) the
prevalence of documented OUD, (2) the prevalence of
office-based medication treatment for OUD, and (3)
patient characteristics associated with OUD medication
treatment.

Methods
Design and sample

This was a cross-sectional, three-year, study using secondary data from Phase 1 of the PRimary care Opioid
Use Disorders (PROUD) trial. The PROUD trial was a
pragmatic, cluster-randomized implementation trial
testing whether a collaborative care model for officebased addiction treatment increased use of medication for OUD in PC (2014–2016) [15]. PROUD Phase
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1 was a preliminary study to identify potential health
systems to participate in the trial and assess the feasibility of cohort identification and data collection [16,
17]. Six of eleven health systems participating in Phase
1 provided data for the present study of youth: Kaiser Permanente (KP) Washington, KP Northwest, KP
Northern California, KP Colorado, Health Partners,
and MultiCare. These included 5 integrated health
delivery and insurance systems with access to claims
data for care received outside the system and one feefor-service community health system serving a mixed
urban, suburban, and rural population (MultiCare).
Sites represented 6 states (Minnesota, Wisconsin, Colorado, California, Oregon, and Washington). Data on
patient demographics and clinical characteristics were
obtained from electronic health records (EHR) and
insurance claims. Medication treatment was based on
pharmacy dispensings in the EHR and claims data (5
integrated health systems) or medication orders in the
EHR (1 health system)—referred to as prescriptions
hereafter, as well as procedure codes (all sites). Data
were not available for methadone treatment in Outpatient Treatment Programs (OTPs).
Patients were eligible if they had at least 1 PC visit in
fiscal years (FY) of 2014–2016, and were 16–25 years old
at the time of their first PC visit. Data were ascertained
from electronic health records (EHR) and insurance
claims data for the FY of their first PC visit during the
study period (“index FY” hereafter). Youth were included
in analyses for their index FY. Youth were divided into 3
age groups: 16–17 years, 18–21 years, and 22–25 years.
These groups were selected to allow comparisons across
developmental stages based on prior work that has
shown differences [18].
Primary outcomes

The primary outcomes were (1) a diagnosis of OUD and
(2) one or more prescription(s) for office-based OUD
medication treatment (hereafter “treatment”) documented in the index FY. OUD was defined using International Classification of Disease-9th edition (ICD-9-CM;
until September 30, 2015) or ICD-10-CM diagnostic
codes (starting October 1, 2015). Codes for both “active”
and “in remission” OUD were included as providers can
differ in their use of the codes (Additional file 1: Table S1).
A prescription for OUD medication was defined as documentation of 1 or more dispensings (5-sites), orders
(1-site), or procedure codes (all sites) for buprenorphine
approved for OUD (transmucosal or implanted) or naltrexone (oral or injectable) in the index FY. Secondarily,
we report on 2 or more prescriptions and/or procedures
in a FY as a proxy for medication taking.
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Patient characteristics

Patient demographics included gender, age, race/ethnicity, and insurance type at the time of first PC visit.
Clinical characteristics were collected in the index FY
and included ICD9/10 diagnoses of other substance use
disorders (tobacco, alcohol, cannabis, and stimulants),
opioid overdose, and psychiatric diagnoses (depression,
anxiety, attention deficit disorder, serious mental illness,
and eating disorder).
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Table 1 Characteristics of youth age 16–25 years with and
without opioid use disorder (OUD)
OUD (N = 2131) No OUD
(N = 301,131)

Female

Characteristics of youth with documented opioid use
disorder

Among 303,262 PC patients 16–25 years old, 2,131 individuals had a documented OUD diagnosis in the index
FY. The prevalence of documented OUD was higher
with increasing age from 0.16% among 16–17 year olds,
to 0.67% among 18–21 year olds, and 1.02% among
22–25 year olds.
Youth with OUD were predominantly male and White,
with a substantial burden of tobacco, alcohol, cannabis,
and stimulant use disorders (Table 1). Over 3% had a
documented opioid overdose in the FY. Table 2 compares
demographic and clinical characteristics in youth with
OUD across the 3 age groups. Rates of documented substance use and mental health comorbidity tended to be
higher in younger patients (Table 2).

40.7

56.1

Race/ethnicity
Hispanic

Analysis

Results

%

Gender

White

We first characterized the demographic and clinical characteristics of youth with and without documented OUD
in the index FY. Among youth with documented OUD,
we described characteristics across the three age groups
(16–17, 18–21, and 22–25 years). The prevalence (95%
confidence intervals [CIs]) of prescriptions for each type
of OUD medication (buprenorphine, injectable naltrexone, and oral naltrexone), as well as no OUD treatment,
were described graphically across age groups. Finally,
we compare the prevalence (95% CIs) of demographic
and clinical characteristics in patients with OUD who
received medication treatment and those who did not, in
the overall sample.
The study was approved by the Kaiser Permanente
Washington Institutional Review Board (IRB), and all
sites ceded to the Kaiser Permanente Washington IRB
except MultiCare who used MultiCare’s IRB for review
and approval.

%

8.7

15.0

77.0

57.1

Black/African American

3.1

7.8

Asian

1.7

10.2

Native American/Alaska Native

0.7

0.4

Hawaiian/Pacific Islander

0.4

0.7

Multiracial

4.7

3.1

Other

0.9

1.0

Unknown

2.8

4.8

Insurance typea
Medicare

0.1

0.4

82.7

83.1

Medicaid and other state subsidized 12.3

10.2

Commercial
Uninsured
Tobacco use disorder

4.8

6.3

53.5

5.3

Alcohol use disorder

24.6

1.4

Cannabis use disorder

32.9

1.6

Stimulant use disorder

27.8

0.3

3.6

0.0

Opioid overdose
Depressive disorders

43.4

12.2

Anxiety disorder

47.4

13.7

Serious mental illnessb

10.1

1.2

Attention Deficit Disorder

13.1

6.0

1.9

0.6

Eating disorder
a

Excludes one health system with missing insurance data

b

Serious mental illness defined as schizophrenia and bipoloar disorder

Proportion of those with documented OUD
with medication treatment

Overall, 35% (95% CI 33–37%) of youth with OUD
received OUD treatment at some time during the index
FY. Among 16–17 year-olds with OUD, 14% received
treatment: 10% buprenorphine, 5% oral naltrexone, and
3% injectable naltrexone (some received more than one
medication) (Fig. 1). For 18–21 year-olds, 32% received
treatment: 28% buprenorphine, 4% oral naltrexone,
and 2% injectable naltrexone. For 22–25 year-olds, 39%
received treatment: 37% buprenorphine, 2% oral naltrexone, and 1% injectable naltrexone.
Overall, 86% of youth receiving buprenorphine had at
least two prescriptions for buprenorphine. In contrast,
only 46% of youth receiving injectable naltrexone and
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Table 2 Characteristics of youth 16–25 years with opioid use
disorder stratified by age
16–
17 years
(N = 119)
%

18–
21 years
(N = 664)
%

22–25 years
(N = 1348)
%

55.5

41.9

38.8

Gender
Female
Race/ethnicity
Hispanic

17.7

9.2

7.7

Caucasian

68.1

75.8

78.4

2.5

2.9

3.3

2.5

2.1

1.5

Native American/Alaska
Native

0.0

0.9

0.6

Hawaiian/Pacific Islander

0.0

0.2

0.5

Multiracial

9.2

5.1

4.0

Other

0.0

0.9

1.0

Unknown

0.0

3.0

3.0

Black/African American
Asian

Insurance typea
Medicare

0.0

0.0

0.2

Commercial

83.0

86.9

80.6

State subsidized

14.8

10.5

13.0

2.3

2.5

6.2

Tobacco use disorder

42.9

56.3

53.0

Alcohol use disorder

45.4

24.0

23.1

Cannabis use disorder

64.7

40.5

26.3

Stimulant use disorder

31.9

30.3

26.3

2.5

3.5

3.7

77.3

43.4

40.4

Anxiety disorder

65.6

46.2

46.3

Serious mental illnessb

15.1

9.3

10.1

Attention Deficit Disorder

31.9

13.0

11.6

3.4

3.2

1.2

Uninsured

Opioid overdose
Depressive disorders

Eating disorder
a

Excludes one health system with missing insurance data

b

Serious mental illness defined as schizophrenia and bipoloar disorder

33% of youth receiving oral naltrexone had at least two
prescriptions for naltrexone.
Youth with documented OUD: comparison of those
with and without medication treatment

In the overall sample with OUD, youth who had OUD
medication treatment were less likely than those without medication treatment to have documented depressive disorder (36% vs. 48%), anxiety disorder (42% vs.
50%), serious mental illness (6.9% vs. 12%) or an eating
disorder (0.8% vs. 2.5%) (Table 3). There were no differences in the prevalence of sex, race/ethnicity, insurance
status, overdose or tobacco or other substance use disorder in those with and without medication treatment.

The age stratified results can be found in Additional
file 2: Appendix S1.

Discussion
Documented diagnosis of OUD increased with age in this
observational study of youth 16 to 25 years old engaged
in PC in 6 large U.S. health systems. Among youth with
documented OUD, approximately 2 in 3 had depressive
or anxiety disorders, half had a tobacco use disorder, 2 in
5 had cannabis use disorders, and 1 in 3 had alcohol or
stimulant disorders documented in their EHRs or health
insurance claims. The prevalence of office-based OUD
medication treatment among youth with OUD increased
with age: fewer than 1 in 6 of youth ages 16–17 received
buprenorphine or naltrexone while approximately 1 in
3 of those 18–25 years received medication treatment.
Buprenorphine was more commonly prescribed compared to naltrexone among all age groups and was more
commonly refilled or reordered after the initial prescription. Youth with OUD who were treated with buprenorphine or naltrexone were less likely than those who were
not to have mental health disorders documented in EHR
or claims data in the same FY.
The prevalence of medication treatment of OUD was
higher in our overall sample than in previous studies of
youth in large commercial and public insurance cohorts
between 2001 and 2018 [12, 13, 19]. In those studies,
4.7% of youth under 18 years covered by Medicaid and
9.7% of youth 16–17 year with commercial insurance
received OUD medications in the three and six months
after diagnosis of OUD, respectively. In our sample,
about 14% of 16–17 year-olds had at least one prescription for OUD medication in a 1 year period. Similarly,
young adults in our sample (18–25 years) had a higher
prevalence of OUD treatment than in prior studies. Hadland et al. found that 22–31% of young adults with Medicaid and commercial insurance received medications for
OUD within 3 months of an OUD diagnosis [12]. In our
sample, 32–39% of young adults received medications
for OUD in a 12 month period. One potential explanation for the higher prevalence of OUD treatment in our
study than in prior studies of youth and young adults, is
that youth in our study might have been more engaged
in medical care. Our study sample included only youth
who had a PC visit in the same year. Further, OUD diagnoses could have occurred within addiction treatment
programs in most study health systems. Prior studies of
youth with nonfatal overdose have found a low prevalence of medication treatment of OUD [18, 20, 21]. In
our study, youth with and without treatment of OUD had
comparable rates of nonfatal OD. Of note, these other
studies evaluated receipt of medication after a new OUD
diagnosis or nonfatal OD. In this study, we report the
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Fig. 1 Proportion of youth with opioid use disorder who receive medication treatment with buprenorphine or naltrexone

prevalence of OUD medications in the same FY as the
OUD diagnosis or nonfatal OD.
In this study, 86% of young people who started
buprenorphine received more than one prescription
while only half who started injectable naltrexone received
more than one prescription. While injectable naltrexone is an effective medication for treating OUD, patients
must be abstinent from opioids prior to starting which is
a challenge for many patients [22]. Although these barriers in naltrexone initiation have been well described in
adult populations [23–25] there are fewer data about naltrexone treatment in youth [12]. Youth in this study were
treated with oral naltrexone as often as injectable naltrexone. Those prescriptions could represent a trial before a
planned transition to injectable naltrexone, but our data
do anot allow further clarification of this. FDA’s approval
of buprenorphine starting at age 16, but approval of naltrexone starting at age 18, may also impact decisions
about medication choices. There is a need for a more
nuanced understanding of how patients, providers, and
families are making decisions about starting and continuing OUD medication treatment.
The prevalence of co-occurring other substance use
disorder and mental health disorders was very high
in this sample of youth with OUD, particularly for
16–17 year olds. Fifty-four percent of youth with OUD
also had a tobacco use disorder. A recent study finding that only ~ 5% of youth with nicotine use disorder
received pharmacotherapy and/or counseling. Ref. [26]
highlights the importance of treating all substance use
disorders in youth once they are engaged in treatment
for OUD. More than half of the youth with OUD in our
study had documented anxiety or depressive symptoms, higher than a prior study of youth in an outpatient

substance use treatment program where the prevalence
was less than 25% [27]. The higher prevalence of cooccurring disorders in the present sample may reflect
the study sample. Some of the study health systems had
internal treatment for mental health and substance use
disorders, which could have led to increased documentation and treatment. It is possible that some patients could
have been diagnosed with OUD in the process of mental health or substance use disorder treatment. However,
this high prevalence also highlights the urgency of providing treatment for mental health and SUD in addition
to OUD. The prevalence of mental health conditions was
lower in patients treated with medications for OUD. This
may indicate that mental health providers—including
prescribers such as psychiatrists—are often not trained
to treat youth with OUD with medications. Given the
high prevalence of mental health disorders, further work
is needed to ensure that providers treating mental health
conditions in youth are prepared to offer evidence-based
treatment.
In this study, more than half of the 16–17 year olds with
an OUD were female. However, the proportion of youth
with OUD who were female decreased as age increased.
Although this is not consistent with one study of Medicaid-insured youth with OUD [12], other studies of
youth experiencing nonfatal opioid overdose have found
a higher proportion of females in younger age groups,
with decreases in the proportion who are female as age
increases [18, 21]. These sex- and age-based differences
in youth with OUD may be the result of secular trends
and warrant future study to ensure that age-appropriate,
tailored interventions are offered to females and males.
Despite the higher treatment prevalence in this
sample compared to prior studies, there remains
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Table 3 Prevalence of demographic and clinical characteristics
and 95% confidence intervals in youth with opioid use
disorder (OUD) with and without documented treatment with
medications for OUD (N = 2131)

Female

Medication
treatmenta (n = 752)
%, (95% CI)

No
treatment
(n = 1379)
%, (95% CI)

38 (35, 42)

42 (39, 45)

Race/ethnicity
Hispanic

8.8 (6.9, 11)

8.7 (7.3, 10)

Caucasian

79 (76, 82)

76 (74, 78)

diagnosis and treatment of OUD; such information
could inform improvements in systems of care for this
population. For those youth receiving specialty mental
health services or other SUD treatment, OUD treatment can be integrated into their other mental health
and SUD care. Most SUD, including OUD, typically first
manifest in the age group that is the focus of this work.
Prioritizing early treatment of OUD would likely move
these young people into a recovery trajectory sooner in
their lifespan to prevent a lifetime of disability.

Black/African American

1.9 (1.0, 3.1)

3.8 (2.9, 5)

Limitations

Asian

1.2 (0.5, 2.3)

2.0 (1.4, 2.9)

NA/AN

0.5 (0.1, 1.4)

0.7 (0.3, 1.3)

There are limitations to this study. First, it is cross-sectional, and we were not able to identify incident OUD
diagnoses or study the temporality of any associations.
In addition, we could not determine whether OUD treatment was prescribed from PC or specialty care settings.
The optimal approach for identifying outpatient prescriptions in EHR-based health services research is to use
pharmacy medication dispensing data; one health system
in this study only had medication orders from the EHR.
Despite also using procedure codes to capture medications administrated in the office at all sites, either data
source may have resulted in some misclassification of
treatment status. We were not able to identify methadone
treatment of OUD. Thus, it is possible that we may have
underestimated OUD treatment to some extent, particularly for those 18 years and over. In addition, the sample
of 16–17 years olds was limited. We previously reported
OUD treatment variation by site, and believe much of the
observed variation is true differences in treatment practices at the sites [16]. The high prevalence of alcohol use
disorder (AUD) in this sample raises the possibility that
some participants were prescribed naltrexone for AUD
and not OUD. Although over 80% of patients received 2
or more buprenorphine prescriptions—suggesting that
buprenorphine was at least initiated by the patient—it is
possible that for some patients the two prescriptions represented the induction prescription and the first home
prescription. This would lead to an overestimate of how
many patients engaged in OUD medication treatment.
Five of the health systems in this analysis have integrated
mental health care, so that these youth could have greater
access to mental health and substance use care than
other youth. This may have led to increased opportunity for and documentation of substance use and mental
health diagnoses. As a result, our findings may not generalize to other health care settings. Finally, health systems
participating in this study were exploring participating in
a future implementation trial treating OUD in PC. Thus,
they may have been more open than other health systems
to providing medications for OUD.

Hawaiian/Pacific Islander

0.8 (0.3, 1.7)

0.1 (0.02, 0.5)

Multiracial

3.9 (2.6, 5.5)

5.1 (4, 6.4)

Other

0.8 (0.3, 1.7)

0.9 (0.5, 1.6)

Unknown

3.1 (1.9, 4.6)

2.7 (1.9, 3.7)

Insuranceb
Medicare

11 (8.7, 13)

13 (11, 16)

Commercial

85 (83, 88)

81 (78, 83)

State subsidized

0 (0, 0.5)

0.2 (0.02, 0.7)

Uninsured

3.8 (2.5, 5.4)

5.6 (4.3, 7.2)

Tobacco UD

56 (52, 59)

52 (50, 55)

Alcohol UD

21 (18, 24)

26 (24, 29)

Cannabis UD

34 (31, 38)

32 (30, 35)

Stimulant UD

30 (26, 33)

27 (25, 29)

OD

3.3 (2.2, 4.9)

3.7 (2.8, 4.8)

Depression

36 (32, 39)

48 (45, 50)

Anxiety

42 (38, 45)

50 (48, 53)

Serious mental illnessc

6.9 (5.2, 9.0)

12 (10, 14)

ADD

11 (9.1, 14)

14 (12, 16)

Eating disorder

0.8 (0.3, 1.7)

2.5 (1.8, 3.5)

NA/AN Native American/Alaskan American, OD opioid overdose, UD use
disorders, ADD attention deficit disorder
Bolded results are significant at p < 0.05
a

One or more prescriptions or procedure codes for buprenorphine and/or
naltrexone in the fiscal year of index visit

b

Excludes one health system with missing insurance data

c

Serious mental illness defined as schizophrenia and bipoloar disorder

a significant opportunity to improve access to and
engagement in medication treatment for youth with
OUD and co-occurring mental health disorders. Offering OUD treatment in PC is not only safe and effective
[28–30], but is also likely more convenient and less
stigmatizing for patients. Moreover, PC and specialty
physicians can treat the patient’s OUD in the context of
their other health needs. Future work should focus on
identifying the provider characteristics associated with
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Conclusions
In this study of over 300,000 patients 16–25 years old
from 6 health systems, 0.7% had a documented OUD.
Among patients with OUD, 65% had no documented
OUD treatment. Significant opportunity exists to
improve access to OUD treatment among affected youth.
Moreover, the high prevalence of other substance use and
mental health disorders among youth with OUD, indicate
an urgent need for treatment of OUDs that also addresses
polysubstance use and mental health disorders.
Abbreviations
PC: Primary care; OUD: Opioid use disorder; FY: Fiscal year; HER: Electronic
health record; AAP: American Academy of Pediatrics.
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